Kosovo

Kosovo

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
4.17 (4.03 - 4.32) 2013 Modelled Schweitzer et al, 2015
Technical notes
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

Women of childbearing age (15–49 years)
Download
Value (%) Year Type Source
0.72 (0.50 - 0.93) 2019 Modelled Dugan et al., 2021
Technical notes

Number of people living with chronic HCV (RNA+/cAg)

Women of childbearing age (15–49 years)
Download
Value Year Type Source
3,400 (2,400 - 4,400) 2019 Modelled Dugan et al., 2021
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
4.17 (%)
2013
(4.03 - 4.32(%))
Schweitzer et al, 2015
No data available

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

No data available

Survey/surveillance

No data available
HBV chart

Modelled

No data available

Survey/surveillance

No data available
HCV chart

Prevalence < 5

No data available

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines